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RSymptoms of Depression
But Not Depressive Disorder
I thank Hoen et al. (1) and the Heart and Soul Study for drawing
ttention to the psychological factors that co-occur with and influence
ardiovascular (CV) disease. Hoen et al. (1) reported exciting results
ith individual symptoms predicting CV events. However, a concern
hat comes to mind is that the symptoms most significantly associated
ith CV prognosis are not depression-specific symptoms. The inves-
igators acknowledged this limitation and made efforts to account for
t. Yet, despite the acknowledgement, are the researchers really
xamining depression? These symptoms (i.e., fatigue, appetite prob-
ems, and sleeping difficulties) could also be considered symptoms of
V disease, or of any other medical condition (e.g., cancer). This
etter is not meant to undermine the importance of these somatic
ymptoms, as they are important for health, prognosis, and recovery,
ut rather to bring attention to the fact that this particular investiga-
ion does not discuss clinical or diagnosable depression. The investi-
ators’ rationale for examining the individual symptoms in light of the
eterogeneity of depression and lack of strong treatment effects on CV
utcomes is understandable; however, a focus on somatic symptoms
ay take us away from the original intention: examining depression
nd CV disease to improve the treatment and outcomes of these
atients. In their paper, Hoen et al. (1) include the prevalence of each
f the depressive symptoms from the Patient Health Questionnaire,
ut they do not state the prevalence of meeting criteria for or being
linically relevant and suggestive of major depressive disorder or other
epressive disorder on the basis of the scoring and interpretation
nstructions of the Patient Health Questionnaire (2). The investiga-
ors hypothesized in the discussion that the lack of a relationship
etween cognitive symptoms and CV events may be due to a smaller
umber of patients reporting cognitive symptoms (p. 843 [1]). The
diagnosis of major depressive disorder requires the presence of
cognitive symptoms (must have either depressed mood or anhedonia
[loss of interest] most of the time for the past 2 weeks), and dysthymic
disorder requires depressed mood (3). Thus, by their own admission,
the majority of these patients did not have depression. It would be
interesting to examine these 3 somatic symptoms (and the other
symptoms of depression) and CV outcomes between CV patients
who had diagnosed depression and those who did not. There is solid
evidence that symptoms of depression (e.g., depressed mood) and
diagnosable depression are risk factors for the development and
progression of CV disease. Individual symptoms do not “make
depression.” We do not want to be too hasty to ignore or discredit the
cognitive symptoms of depression that exist, individually and as they
relate to somatic symptoms and CV events, particularly in patients
with CV disease.
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Reply
In her comments regarding our paper (1), Dr. Serber correctly points out
that a diagnosis of major depressive disorder (MDD) requires the
presence of at least 1 cognitive symptom (depressedmood or anhedonia).
Therefore, somatic symptoms alone do not “make depression.” At Dr.
Serber’s suggestion, we analyzed the effects of individual somatic symp-
toms on cardiovascular prognosis in patients with and without current
MDD (on the basis of the computerizedDiagnostic Interview Schedule).
Overall, the somatic symptoms were more strongly predictive of cardio-
vascular events in patients withoutMDD (n 795) than in patients with
MDD (n 222). This finding supports Dr. Serber’s hypothesis that the
cardiotoxicity of the somatic symptoms was not necessarily related to
depression. Notably, the increased risk of cardiovascular events in patients
with somatic symptoms was independent of several important confound-
ers, including history of myocardial infarction, history of heart failure, and
left ventricular ejection fraction. However, although controlling for
confounders serves a useful function, it cannot transform observational
data into natural experiments (2). Therefore, it remains possible that the
association we found between specific symptoms and increased risk of
cardiac events was due to worse cardiovascular disease severity that was
not otherwise accounted for in our multivariate models. For future
studies, it will be important to focus on the relationship between somatic
symptoms and cardiovascular disease, including the issue of confounding.
*Petra W. Hoen, BSc
Mary A. Whooley, MD
Peter de Jonge, PhD
*Interdisciplinary Center for Psychiatric Epidemiology
UMCG, CC72
Hanzeplein 1
9713 GZ Groningen
the Netherlands
E-mail: p.w.hoen@med.umcg.nldoi:10.1016/j.jacc.2010.11.035
a
S
c
C
p
r
t
p
l
1
p
w
5
c
t
c
T
p
a
o
t
*
*
R
C
B
D
D
E
R
e
d
*
*
U
1
G
U
E
R
1569JACC Vol. 57, No. 14, 2011 Correspondence
April 5, 2011:1568–71REFERENCES
1. Hoen PW, Whooley MA, Martens EJ, Na B, van Melle JP, de Jonge
P. Differential associations between specific depressive symptoms and
cardiovascular prognosis in patients with stable coronary heart disease.
J Am Coll Cardiol 2010;56:838–44.
2. Christenfeld NJ, Sloan RP, Carroll D, Greenland S. Risk factors,
confounding, and the illusion of statistical control. Psychosom Med
2004;66:868–75.
Low Coenzyme Q10 Levels
nd the Outcome of
tatin Treatment in Heart Failure
McMurray et al. (1) investigated in a pre-specified substudy of
CORONA (Controlled Rosuvastatin Multinational Study in Heart
Failure) the effect of statin therapy on plasma coenzyme Q10 (CoQ10)
oncentration and the possible relationship between the level of
oQ10 and cardiovascular events. Depletion of tissue CoQ10, a
owerful natural antioxidant and an essential component of the
espiratory chain, might explain at least in part the neutral outcome of
he rosuvastatin study. Rosuvastatin treatment at 10 mg/day reduced
lasma CoQ10 significantly by 39%, down to a median level that was
ower than the baseline level of CoQ10 in patients classified in tertile
(0.48 g/ml). With a focus on the number of clinical outcomes in
atients in tertile 1, more patients in the rosuvastatin group compared
ith those receiving placebo experienced primary end points (72 vs.
9, respectively); also, greater all-cause mortality (78 vs. 67) and
oronary end points (54 vs. 45) were recorded in the rosuvastatin-
reated patients. These differences were calculated to be not statisti-
ally significant but according to the undersigned clinically relevant.
he investigators expressed some caution in their discussion of a
ossible adverse effect of statin treatment in patients with low CoQ10
levels: “We cannot completely exclude an adverse effect,” and “we had
limited statistical power to exclude this possibility” (1). In a previous
study by Molyneux et al. (2), the investigators found low CoQ10
concentration to be an independent predictor of mortality in patients
with heart failure, and the association was even stronger than with
N-terminal pro–B-type natriuretic peptide.
The optimal design of a controlled statin trial in heart failure
should have a CoQ10 plus statin arm to evaluate outcomes in 2
spects: 1) to avoid further depletion of the plasma and tissue levels
f CoQ10 in heart failure (3); and 2) to derive advantage from a
possible therapeutic effect of CoQ10 in addition to conventional
herapy (4).
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Reply
Plasma coenzyme Q10 (CoQ10) concentration was not an indepen-
dent predictor of any major clinical outcome in the elderly patients
with quite advanced heart failure in CORONA (Controlled Rosuv-
astatin Multinational Study in Heart Failure) (1). Looking at the
outcomes that should be most sensitive to any harmful effect of
lowering CoQ10, there was no convincing effect of rosuvastatin on
ither the risk for heart failure hospitalization or the composite of
eath or heart failure hospitalization. Prior studies of CoQ10 supple-
mentation in heart failure have not shown any convincing benefit.
Although it would be of interest to study a statin with and without
CoQ10 supplementation, such a trial is very unlikely to be conducted.
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Assessment of Psychosocial Risk
Factors Is Missing in the
2010 ACCF/AHA Guideline
for Assessment of Cardiovascular
Risk in Asymptomatic Adults
Despite the amount of evidence supporting significant and indepen-
dent associations between psychosocial factors and the pathogenesis of
cardiovascular disease (1–5), the 2010 American College of Cardiol-
ogy Foundation/American Heart Association Guideline for Assess-
ment of Cardiovascular Risk in Asymptomatic Adults (6) does not
consider any of them and does not provide any justification for that
decision. This is surprising because many studies have shown that
